High fructose intake is increasingly recognized as causative in development of prediabetes, metabolic syndrome and cardiovascular disease (CVD). The mechanisms underlying fructose-induced metabolic disturbances are unclear but are beginning to be unraveled. In contrast to metabolism of glucose, the breakdown of fructose leads to the generation of metabolites that stimulate hepatic de novo lipogenesis (DNL) and increased levels of both fasting and postprandial triglycerides. The key lipogenic transcription factor seems to be activated by fructose independently of insulin. However, it is still controversial whether fructose consumption increases DNL in man to the extent that it induces metabolic disturbances. Animal studies have shown that also the adipose tissue is responsive to fructose feeding fructose, and that high fructose-feeding induces insulin resistance and inflammation in the adipose tissue. The role of intestinal insulin resistance in fructose-induced dysmetabolism has not been studied in detail. The critical question is whether the metabolic disturbances are induced by calorie excess or by fructose per se.
Detailed description: Study subjects will participate to studies 1-4 before and 3 m after fructose diet: 1. An oral fat load or a kinetic study with stable isotopes combined with an oral fat load. 2. Determination of liver, subcutaneous and intra-abdominal fat. (Proton magnetic resonance spectroscopy ) 3. Lipolytic enzymes, advanced lipid analysis, fat biopsies and genetic studies and gut microbiota profiling 4. Oral glucose tolerance test and analysis of incretins and inflammatory biomarkers.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
82
3 month fructose diet 75 g/day
Université Laval
Québec, Canada
Helsinki University Central Hospital, Biomedicum
Helsinki, Finland
University of Naples, Federico II, and Faculty of Medicine
Naples, Italy
Sahlgrenska Academy at University of Gothenburg and Sahlgrenska University Hospital
Gothenburg, Sweden
TG Plasma AUC
Before vs. after fructose challenge: Triglycerides (TG) plasma Area Under Curve (AUC)
Time frame: Form the baseline (time point 1) to end of treatment at 3 months (time point 2)
B48 Plasma AUC
Before vs. after fructose challenge: apolipoprotein (apo)B48 plasma Area Under Curve (AUC)
Time frame: Form the baseline (time point 1) to end of treatment at 3 months (time point 2)
TG Plasma iAUC
Before vs. after fructose challenge:Triglycerides (TG) plasma incremental Area Under Curve (iAUC)
Time frame: Form the baseline (time point 1) to end of treatment at 3 months (time point 2)
DNL
Before vs. after fructose challenge: de novo lipogenesis (DNL)
Time frame: Form the baseline (time point 1) to end of treatment at 3 months (time point 2)
ApoC-III
Before vs. after fructose challenge: Apolipoprotein C-III (ApoC-III)
Time frame: Form the baseline (time point 1) to end of treatment at 3 months (time point 2)
β-OH Butyrate
Before vs. after fructose challenge: beta-OH butyrate (β-OH butyrate)
Time frame: Form the baseline (time point 1) to end of treatment at 3 months (time point 2)
Liver Fat
Before vs. after fructose challenge
Time frame: Form the baseline (time point 1) to end of treatment at 3 months (time point 2)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.